The stock price of AMGEN Inc. (NASDAQ: AMGN) has plunged by -1.40 when compared to previous closing price of 335.61, but the company has seen a -0.56% decline in its stock price over the last five trading sessions. reuters.com reported 2024-09-24 that Amgen said on Tuesday its experimental drug, rocatinlimab, met the main goals in a late stage study testing it as a treatment for a skin condition known as atopic dermatitis.
Is It Worth Investing in AMGEN Inc. (NASDAQ: AMGN) Right Now?
The price-to-earnings ratio for AMGEN Inc. (NASDAQ: AMGN) is above average at 57.01x. The 36-month beta value for AMGN is also noteworthy at 0.61. There are mixed opinions on the stock, with 7 analysts rating it as a “buy,” 3 rating it as “overweight,” 15 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for AMGN is 536.01M, and at present, short sellers hold a 1.58% of that float. The average trading volume of AMGN on September 25, 2024 was 1.99M shares.
AMGN’s Market Performance
AMGN stock saw an increase of -0.56% in the past week, with a monthly gain of 0.64% and a quarterly increase of 3.64%. The volatility ratio for the week is 1.65%, and the volatility levels for the last 30 days are 1.81% for AMGEN Inc. (AMGN). The simple moving average for the last 20 days is 0.11% for AMGN stock, with a simple moving average of 9.55% for the last 200 days.
Analysts’ Opinion of AMGN
Many brokerage firms have already submitted their reports for AMGN stocks, with Wells Fargo repeating the rating for AMGN by listing it as a “Equal Weight.” The predicted price for AMGN in the upcoming period, according to Wells Fargo is $335 based on the research report published on August 07, 2024 of the current year 2024.
Barclays gave a rating of “Equal Weight” to AMGN, setting the target price at $300 in the report published on May 03rd of the current year.
AMGN Trading at 0.40% from the 50-Day Moving Average
After a stumble in the market that brought AMGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -4.59% of loss for the given period.
Volatility was left at 1.81%, however, over the last 30 days, the volatility rate increased by 1.65%, as shares surge +1.27% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +0.23% upper at present.
During the last 5 trading sessions, AMGN fell by -0.56%, which changed the moving average for the period of 200-days by +22.86% in comparison to the 20-day moving average, which settled at $330.78. In addition, AMGEN Inc. saw 14.89% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AMGN starting from Grygiel Nancy A., who sale 2,117 shares at the price of $313.09 back on May 03 ’24. After this action, Grygiel Nancy A. now owns 9,883 shares of AMGEN Inc., valued at $662,802 using the latest closing price.
Grygiel Nancy A., the SVP & CCO of AMGEN Inc., sale 2,096 shares at $273.03 during a trade that took place back on Dec 04 ’23, which means that Grygiel Nancy A. is holding 10,874 shares at $572,276 based on the most recent closing price.
Stock Fundamentals for AMGN
Current profitability levels for the company are sitting at:
- 0.2 for the present operating margin
- 0.63 for the gross margin
The net margin for AMGEN Inc. stands at 0.1. The total capital return value is set at 0.09. Equity return is now at value 49.27, with 3.46 for asset returns.
Based on AMGEN Inc. (AMGN), the company’s capital structure generated 0.91 points at debt to capital in total, while cash flow to debt ratio is standing at 0.1. The debt to equity ratio resting at 10.57. The interest coverage ratio of the stock is 1.89.
Currently, EBITDA for the company is 14.8 billion with net debt to EBITDA at 4.7. When we switch over and look at the enterprise to sales, we see a ratio of 7.5. The receivables turnover for the company is 4.45for trailing twelve months and the total asset turnover is 0.34. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.26.
Conclusion
In summary, AMGEN Inc. (AMGN) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
